Why is Medicamen Biotec falling/rising?

As of 13-Aug, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at Rs. 342.80, which reflects a decrease of Rs. 13.15 or 3.69%. The stock has hit a new 52-week low today at Rs. 342.75 and has been on a downward trend for the last 10 days, resulting in a total drop of 14.3% during this period. The stock has underperformed its sector by 5.18% today and is trading below all key moving averages, indicating a bearish sentiment. Additionally, the stock has shown significant underperformance over various time frames, with a year-to-date decline of 32.69% compared to a 3.07% increase in the benchmark index. The company's financial health is concerning, with a low return on capital employed (ROCE) of 2.8 and a high debt-equity ratio of 0.16, which reflects poor long-term growth prospects.
In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as it has generated negative returns while the Sensex has remained relatively flat, with only a 0.01% decline over the past week. This consistent underperformance against the benchmark over the last three years, coupled with declining profits and a negative growth rate in operating profit, has contributed to a lack of investor confidence. While there has been a slight increase in delivery volume, indicating some investor interest, the overall sentiment remains negative due to the company's financial struggles and the significant drop in stock value.